Dr. Robert D. Arnold

(Reading, Writing, Speaking)

University of Georgia Research Foundation: Small animal models of primary and metastatic prostate and breast tumors expressing green fluorescent protein; evaluation of novel drug carriers, $8,500, 2007 to 2008.
Georgia Institute of Technology - University of Georgia Seed Grant Proposal: Development of Nanoparticulate Drug Carriers for Novel Selenium-Based Therapeutic Agents, $100,000, 2007 to 2009.
American Association of Colleges of Pharmacy/American Foundation for Pharmaceutical Education, New Investigators Program for Pharmacy Faculty: sPLA2-Targeted Liposomes for Prostate Cancer, $10,000, 2007 to 2008.
Grayson Jockey Club Research Foundation Inc.: Targeting 5-HT in equine laminitis, $50,292, 2007 to 2009.
Georgia Cancer Coalition: Distinguished Cancer Clinicians & Scientists Program, $250,000, 2007 to 2012.
University of Georgia Research Foundation: Mechanism based development of drug nano-delivery systems for the treatment of cancer, $8,500, 2006 to 2007.
Randy Ellison cancer Research Fund - Seed Grant: Endosomal targeting of Topotecan Liposomes, $2,000, 2006 to 2007.
Mark Diamond Graduate Reserach Fund, University at Buffalo: Liposome Mediated Alterations in Tumor Vascular Permeability, $1,140, 2002 to 2003.

• Bulitta JB, Zhao P, Arnold RD, Kessler DR, Daifuku R, Pratt J, Luciano G, Hanauske AR, Gelderblom H, Awada A, Jusko WJ (Sep 2008) Multiple-pool cell lifespan models for neutropenia to assess the population pharmacodynamics of unbound paclitaxel from two formulations in cancer patients., Cancer chemotherapy and pharmacology
• Bulitta JB, Zhao P, Arnold RD, Kessler DR, Daifuku R, Pratt J, Luciano G, Hanauske AR, Gelderblom H, Awada A, Jusko WJ (Sep 2008) Mechanistic population pharmacokinetics of total and unbound paclitaxel for a new nanodroplet formulation versus Taxol in cancer patients., Cancer chemotherapy and pharmacology
• Carl, S.M., Knipp, G.T., Hussain, A., Morris, K.R., Lindley, D.J., Arnold, R.D. (2008) Biotechnology Product Development, Pharmaceutical Manufacturing Handbook, John Wiley and Sons, In Press, ISBN=978-0-471-213 (bookchapter)
• O'Connor R, O'Leary M, Ballot J, Collins CD, Kinsella P, Mager DE, Arnold RD, O'Driscoll L, Larkin A, Kennedy S, Fennelly D, Clynes M, Crown J (Jan 2007) A phase I clinical and pharmacokinetic study of the multi-drug resistance protein-1 (MRP-1) inhibitor sulindac, in combination with epirubicin in patients with advanced cancer., Cancer chemotherapy and pharmacology, 59 (1), 79-87
• Arnold RD, Mager DE, Slack JE, Straubinger RM (Dec 2005) Effect of repetitive administration of Doxorubicin-containing liposomes on plasma pharmacokinetics and drug biodistribution in a rat brain tumor model., Clinical cancer research : an official journal of the American Association for Cancer Research, 11 (24 Pt 1), 8856-65
• Arnold RD, Slack JE, Straubinger RM (Sep 2004) Quantification of Doxorubicin and metabolites in rat plasma and small volume tissue samples by liquid chromatography/electrospray tandem mass spectroscopy., Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 808 (2), 141-52
• Arnold, R.D.,, Slack, J.E., Mager, D.E., R., Spernyak, J., Mazurchuk, R., Straubinger, R. (2004) Altered plasma pharmacokinetics, tumor/tissue biodistribution, and barrier properties of the tumor microvasculature in rats following repetitive dosing of doxorubicin liposomes, Advances in Liposomes: New Technologies and New Therapies, Chicago, IL
• Robert D. Arnold, Tumor Antivascular Effects of Liposome-Incorporated Drugs, Ph.D. Dissertation, Ann Arbor, MI, University Microfilms International, AAT:3125688, Spring 2004
• Arnold, R.D.,, Slack, J.E., Mager, D.E., and Straubinger, R., (2004) Increased brain tumor deposition of doxorubicin liposomes following repetitive dosing: alterations in plasma pharmacokinetics and barrier properties of the tumor microvasculature in rats, AAPS National Meeting, Baltimore, MD, PharmSci, 5:T3324 pages
• Arnold, R.D.,, Slack, J.E., Mager, D.E., and Straubinger R.M. (2004) Effect of repetitive administration of doxorubicin encapsulated in sterically stabilized liposomes on plasma kinetics, brain tumor/tissue drug deposition, and tumor vascular permeability in Rats, AACR National Meeting, Orlando, FL, Proc. Amer. Assoc. Cancer Res., 45:648 pages
• Straubinger RM, Arnold RD, Zhou R, Mazurchuk R, Slack JE (Mar-Apr 2004) Antivascular and antitumor activities of liposome-associated drugs, Anticancer Research, 24 (2A), 397-404
• Arnold, R.D.,, Slack, J.E., Zhou, R., Mazurchuk, Chau, R.I., and Straubinger R.M. (2003) Antivascular effect of doxorubicin liposomes in a rat brain tumor model, AAPS National Meeting, Salt Lake City, UT, AAPS PharmSci, 5:T3141 pages
• Arnold, R.D.,, Slack, J.E., and Straubinger R.M. (2003) Analysis of doxorubicin in rat tissues by liquid chromatography tandem mass spectroscopy (LC-MS/MS), AAPS National Meeting, Salt Lake City, UT, AAPS PharmSci, 5:R6001 pages
• Straubinger RM, Arnold RD, Zhou R, Mazurchuk R, Slack JE, Antivascular and antitumor activities of liposome-associated drugs., Anticancer research, 24 (2A), 397-404
• Arnold, R.D., Balasubramanian, S., Straubinger, R.M, Liposomal formulation of TNP-470 and plasma stability, Unpublished
• Arnold, R.D., Slack, J.E., and Straubinger R.M., Enhanced tumor vascular permeability with repetitive administration of doxorubicin-containing liposomes in a rat brain tumor model, Submitted